Advertisement

Role of Macrophage Dopamine Receptors in Mediating Cytokine Production: Implications for Neuroinflammation in the Context of HIV-Associated Neurocognitive Disorders

  • R. A. Nolan
  • R. Muir
  • K. Runner
  • E. K. Haddad
  • P. J. Gaskill
ORIGINAL ARTICLE

Abstract

Despite the success of combination anti-retroviral therapy (cART), around 50% of HIV-infected individuals still display a variety of neuropathological and neurocognitive sequelae known as NeuroHIV. Current research suggests these effects are mediated by long-term changes in CNS function in response to chronic infection and inflammation, and not solely due to active viral replication. In the post-cART era, drug abuse is a major risk-factor for the development of NeuroHIV, and increases extracellular dopamine in the CNS. Our lab has previously shown that dopamine can increase HIV infection of primary human macrophages and increase the production of inflammatory cytokines, suggesting that elevated dopamine could enhance the development of HIV-associated neuropathology. However, the precise mechanism(s) by which elevated dopamine could exacerbate NeuroHIV, particularly in chronically-infected, virally suppressed individuals remain unclear. To determine the connection between dopaminergic alterations and HIV-associated neuroinflammation, we have examined the impact of dopamine exposure on macrophages from healthy and virally suppressed, chronically infected HIV patients. Our data show that dopamine treatment of human macrophages isolated from healthy and cART-treated donors promotes production of inflammatory mediators including IL-1β, IL-6, IL-18, CCL2, CXCL8, CXCL9, and CXCL10. Furthermore, in healthy individuals, dopamine-mediated modulation of specific cytokines is correlated with macrophage expression of dopamine-receptor transcripts, particularly DRD5, the most highly-expressed dopamine-receptor subtype. Overall, these data will provide more understanding of the role of dopamine in the development of NeuroHIV, and may suggest new molecules or pathways that can be useful as therapeutic targets during HIV infection.

Keywords

Dopamine Macrophages Neuroinflammation HIV cART 

Abbreviations

cART

Combination anti-retroviral therapy

BG

Basal ganglia

DA

Dopamine

DR

Dopamine receptor

HAND

HIV-associated neurocognitive disorder

M-CSF

Macrophage colony stimulating factor

MDM

Monocyte derived-macrophages

PBMC

Peripheral blood mononuclear cells

SbN

Substantia nigra

Notes

Supplementary material

11481_2018_9825_MOESM1_ESM.pdf (1005 kb)
ESM 1 (PDF 1004 kb)

References

  1. Agius M, Bonnici H (2017) Antidepressants in use in clinical practice. Psychiatr Danub 29:667–671PubMedGoogle Scholar
  2. Agrawal L, Louboutin JP, Marusich E, Reyes BA, Van Bockstaele EJ, Strayer DS (2010) Dopaminergic neurotoxicity of HIV-1 gp120: reactive oxygen species as signaling intermediates. Brain Res 1306:116–130CrossRefPubMedGoogle Scholar
  3. Anthony IC, Bell JE (2008) The Neuropathology of HIV/AIDS. Int Rev Psychiatry 20:15–24CrossRefPubMedPubMedCentralGoogle Scholar
  4. Aquaro S, Bagnarelli P, Guenci T, De Luca A, Clementi M, Balestra E, Calio R, Perno CF (2002) Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus. J Med Virol 68:479–488CrossRefPubMedGoogle Scholar
  5. Armah KA, McGinnis K, Baker J, Gibert C, Butt AA, Bryant KJ, Goetz M, Tracy R, Oursler KK, Rimland D, Crothers K, Rodriguez-Barradas M, Crystal S, Gordon A, Kraemer K, Brown S, Gerschenson M, Leaf DA, Deeks SG, Rinaldo C, Kuller LH, Justice A, Freiberg M (2012) HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis 55:126–136CrossRefPubMedPubMedCentralGoogle Scholar
  6. Aylward EH, Henderer JD, McArthur JC, Brettschneider PD, Harris GJ, Barta PE, Pearlson GD (1993) Reduced basal ganglia volume in HIV-1-associated dementia: results from quantitative neuroimaging. Neurology 43:2099–2104CrossRefPubMedGoogle Scholar
  7. Aylward EH, Brettschneider PD, McArthur JC, Harris GJ, Schlaepfer TE, Henderer JD, Barta PE, Tien AY, Pearlson GD (1995) Magnetic resonance imaging measurement of gray matter volume reductions in HIV dementia. Am J Psychiatry 152:987–994CrossRefPubMedGoogle Scholar
  8. Baker LM, Paul RH, Heaps-Woodruff JM, Chang JY, Ortega M, Margolin Z, Usher C, Basco B, Cooley S, Ances BM (2015) The effect of central nervous system penetration effectiveness of highly active antiretroviral therapy on neuropsychological performance and neuroimaging in HIV infected individuals. J Neuroimmune Pharmacol 10:487–492CrossRefPubMedPubMedCentralGoogle Scholar
  9. Barnes MA, Carson MJ, Nair MG (2015) Non-traditional cytokines: how catecholamines and adipokines influence macrophages in immunity, metabolism and the central nervous system. Cytokine 72:210–219CrossRefPubMedPubMedCentralGoogle Scholar
  10. Basu S, Dasgupta PS (2000) Dopamine, a neurotransmitter, influences the immune system. J Neuroimmunol 102:113–124CrossRefPubMedGoogle Scholar
  11. Basu S, Chwastiak LA, Bruce RD (2005) Clinical management of depression and anxiety in HIV-infected adults. AIDS 19:2057–2067CrossRefPubMedGoogle Scholar
  12. Berger JR, Arendt G (2000) HIV dementia: the role of the basal ganglia and dopaminergic systems. J Psychopharmacol 14:214–221CrossRefPubMedGoogle Scholar
  13. Berger JR, Kumar M, Kumar A, Fernandez JB, Levin B (1994) Cerebrospinal fluid dopamine in HIV-1 infection. AIDS 8:67–71CrossRefPubMedGoogle Scholar
  14. Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, Turner BJ, Eggan F, Beckman R, Vitiello B, Morton SC, Orlando M, Bozzette SA, Ortiz-Barron L, Shapiro M (2001) Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 58:721–728CrossRefPubMedGoogle Scholar
  15. Boban J, Kozic D, Turkulov V, Ostojic J, Semnic R, Lendak D, Brkic S (2017) HIV-associated neurodegeneration and neuroimmunity: multivoxel MR spectroscopy study in drug-naive and treated patients. Eur Radiol 27:4218–4236CrossRefPubMedGoogle Scholar
  16. Bone NB, Liu Z, Pittet JF, Zmijewski JW (2017) Frontline Science: D1 dopaminergic receptor signaling activates the AMPK-bioenergetic pathway in macrophages and alveolar epithelial cells and reduces endotoxin-induced ALI. J Leukoc Biol 101:357–365CrossRefPubMedGoogle Scholar
  17. Burdo TH, Lackner A, Williams KC (2013) Monocyte/macrophages and their role in HIV neuropathogenesis. Immunol Rev 254:102–113CrossRefPubMedPubMedCentralGoogle Scholar
  18. Calderon TM, Williams DW, Lopez L, Eugenin EA, Cheney L, Gaskill PJ, Veenstra M, Anastos K, Morgello S, Berman JW (2017) Dopamine increases CD14+CD16+ monocyte transmigration across the blood brain barrier: implications for substance abuse and HIV Neuropathogenesis. J Neuroimmune Pharmacol 12:353–370CrossRefPubMedPubMedCentralGoogle Scholar
  19. Capellino S, Cosentino M, Wolff C, Schmidt M, Grifka J, Straub RH (2010) Catecholamine-producing cells in the synovial tissue during arthritis: modulation of sympathetic neurotransmitters as new therapeutic target. Ann Rheum Dis 69:1853–1860CrossRefPubMedGoogle Scholar
  20. Carboni E, Imperato A, Perezzani L, Di Chiara G (1989) Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats. Neuroscience 28:653–661CrossRefPubMedGoogle Scholar
  21. Cecchelli C, Grassi G, Pallanti S (2010) Aripiprazole improves depressive symptoms and immunological response to antiretroviral therapy in an HIV-infected subject with resistant depression. Case Rep Med 2010:836214CrossRefPubMedPubMedCentralGoogle Scholar
  22. Chan P, Brew BJ (2014) HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment. Curr HIV/AIDS Rep 11:317–324CrossRefPubMedGoogle Scholar
  23. Chan P, Hellmuth J, Spudich S, Valcour V (2016) Cognitive impairment and persistent CNS injury in treated HIV. Current HIV/AIDS Reports 13:209–217CrossRefPubMedPubMedCentralGoogle Scholar
  24. Chi DS, Qui M, Krishnaswamy G, Li C, Stone W (2003) Regulation of nitric oxide production from macrophages by lipopolysaccharide and catecholamines. Nitric Oxide 8:127–132CrossRefPubMedGoogle Scholar
  25. Churchill M, Nath A (2013) Where does HIV hide? A focus on the central nervous system. Curr Opin HIV AIDS 8:165–169CrossRefPubMedPubMedCentralGoogle Scholar
  26. Clifford KM, Samboju V, Cobigo Y, Milanini B, Marx GA, Hellmuth JM, Rosen HJ, Kramer JH, Allen IE, Valcour VG (2017) Progressive brain atrophy despite persistent viral suppression in HIV over age 60. J Acquir Immune Defic Syndr 76:289–297CrossRefPubMedPubMedCentralGoogle Scholar
  27. Cohen LJ, Sclar DA, Culpepper L, Flockhart DA, Hirschfeld RM, Thase ME, VanDenBerg CM (2012) Discussion: a fresh look at monoamine oxidase inhibitors for depression. J Clin Psychiatry 73(Suppl 1):42–45CrossRefPubMedGoogle Scholar
  28. Coley JS, Calderon TM, Gaskill PJ, Eugenin EA, Berman JW (2015) Dopamine increases CD14+CD16+ monocyte migration and adhesion in the context of substance abuse and HIV Neuropathogenesis. PLoS One 10:e0117450CrossRefPubMedPubMedCentralGoogle Scholar
  29. Cools R, D'Esposito M (2011) Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biol Psychiatry 69:e113–e125CrossRefPubMedPubMedCentralGoogle Scholar
  30. Cross HM, Combrinck MI, Joska JA (2013) HIV-associated neurocognitive disorders: antiretroviral regimen, central nervous system penetration effectiveness, and cognitive outcomes. S Afr Med J 103:758–762CrossRefPubMedGoogle Scholar
  31. Currier MB, Molina G, Kato M (2003) A prospective trial of sustained-release bupropion for depression in HIV-seropositive and AIDS patients. Psychosomatics 44:120–125CrossRefPubMedGoogle Scholar
  32. Cysique LA, Heaton RK, Kamminga J, Lane T, Gates TM, Moore DM, Hubner E, Carr A, Brew BJ (2014) HIV-associated neurocognitive disorder in Australia: a case of a high-functioning and optimally treated cohort and implications for international neuroHIV research. J Neuro-Oncol 20:258–268Google Scholar
  33. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9:46–56CrossRefPubMedPubMedCentralGoogle Scholar
  34. D'Aquila PS, Collu M, Gessa GL, Serra G (2000) The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol 405:365–373CrossRefPubMedGoogle Scholar
  35. Daskalopoulou M, Rodger A, Phillips AN, Sherr L, Speakman A, Collins S, Elford J, Johnson MA, Gilson R, Fisher M, Wilkins E, Anderson J, McDonnell J, Edwards S, Perry N, O'Connell R, Lascar M, Jones M, Johnson AM, Hart G, Miners A, Geretti AM, Burman WJ, Lampe FC (2014) Recreational drug use, polydrug use, and sexual behaviour in HIV-diagnosed men who have sex with men in the UK: results from the cross-sectional ASTRA study. Lancet HIV 1:e22–e31CrossRefPubMedGoogle Scholar
  36. Devoino LV, Al'perina EL, Gevorgyan MM, Cheido MA (2006) Interaction between dopamine D1 and D2 receptors in modulation of the immune response. Bull Exp Biol Med 141:553–555CrossRefPubMedGoogle Scholar
  37. Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 85:5274–5278CrossRefPubMedPubMedCentralGoogle Scholar
  38. di Rocco A, Bottiglieri T, Dorfman D, Werner P, Morrison C, Simpson D (2000) Decreased homovanilic acid in cerebrospinal fluid correlates with impaired neuropsychologic function in HIV-1-infected patients. Clin Neuropharmacol 23:190–194CrossRefPubMedGoogle Scholar
  39. Do AN, Rosenberg ES, Sullivan PS, Beer L, Strine TW, Schulden JD, Fagan JL, Freedman MS, Skarbinski J (2014) Excess burden of depression among HIV-infected persons receiving medical care in the United States: data from the medical monitoring project and the behavioral risk factor surveillance system. PLoS One 9:e92842CrossRefPubMedPubMedCentralGoogle Scholar
  40. Faraj BA, Camp VM, Davis DC, Kutner M, Cotsonis GA, Holloway T (1993) Elevated concentrations of dopamine sulfate in plasma of cocaine abusers. Biochem Pharmacol 46:1453–1457CrossRefPubMedGoogle Scholar
  41. Farber K, Pannasch U, Kettenmann H (2005) Dopamine and noradrenaline control distinct functions in rodent microglial cells. Mol Cell Neurosci 29:128–138CrossRefPubMedGoogle Scholar
  42. Ferris MJ, Frederick-Duus D, Fadel J, Mactutus CF, Booze RM (2009) In vivo microdialysis in awake, freely moving rats demonstrates HIV-1 Tat-induced alterations in dopamine transmission. Synapse 63:181–185CrossRefPubMedPubMedCentralGoogle Scholar
  43. Festa L, Gutoskey CJ, Graziano A, Waterhouse BD, Meucci O (2015) Induction of interleukin-1beta by human immunodeficiency virus-1 viral proteins leads to increased levels of neuronal ferritin heavy chain, synaptic injury, and deficits in flexible attention. J Neurosci 35:10550–10561CrossRefPubMedPubMedCentralGoogle Scholar
  44. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295–1300CrossRefPubMedGoogle Scholar
  45. Fitting S, Booze RM, Mactutus CF (2015) HIV-1 proteins, Tat and gp120, target the developing dopamine system. Curr HIV Res 13:21–42CrossRefPubMedPubMedCentralGoogle Scholar
  46. Floresco SB (2013) Prefrontal dopamine and behavioral flexibility: shifting from an "inverted-U" toward a family of functions. Front Neurosci 7:62CrossRefPubMedPubMedCentralGoogle Scholar
  47. Fujimura RK, Goodkin K, Petito CK, Douyon R, Feaster DJ, Concha M, Shapshak P (1997) HIV-1 proviral DNA load across neuroanatomic regions of individuals with evidence for HIV-1-associated dementia. J Acquir Immune Defic Syndr Hum Retrovirol 16:146–152CrossRefPubMedGoogle Scholar
  48. Garcia-Tornadu I, Ornstein AM, Chamson-Reig A, Wheeler MB, Hill DJ, Arany E, Rubinstein M, Becu-Villalobos D (2010) Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance. Endocrinology 151:1441–1450CrossRefPubMedGoogle Scholar
  49. Garin N, Velasco C, De Pourcq JT, Lopez B, Gutierrez Mdel M, Haro JM, Feliu A, Mangues MA, Trilla A (2015) Recreational drug use among individuals living with HIV in Europe: review of the prevalence, comparison with the general population and HIV guidelines recommendations. Front Microbiol 6:690PubMedPubMedCentralGoogle Scholar
  50. Gaskill PJ, Calderon TM, Luers AJ, Eugenin EA, Javitch JA, Berman JW (2009) Human immunodeficiency virus (HIV) infection of human macrophages is increased by dopamine: a bridge between HIV-associated neurologic disorders and drug abuse. Am J Pathol 175:1148–1159CrossRefPubMedPubMedCentralGoogle Scholar
  51. Gaskill PJ, Carvallo L, Eugenin EA, Berman JW (2012) Characterization and function of the human macrophage dopaminergic system: implications for CNS disease and drug abuse. J Neuroinflammation 9:203CrossRefPubMedPubMedCentralGoogle Scholar
  52. Gaskill PJ, Calderon TM, Coley JS, Berman JW (2013) Drug induced increases in CNS dopamine alter monocyte, macrophage and T cell functions: implications for HAND. J Neuroimmune Pharmacol 8:621–642CrossRefPubMedPubMedCentralGoogle Scholar
  53. Gaskill PJ, Yano HH, Kalpana GV, Javitch JA, Berman JW (2014) Dopamine receptor activation increases HIV entry into primary human macrophages. PLoS One 9:e108232CrossRefPubMedPubMedCentralGoogle Scholar
  54. Gaskill PJ, Miller DR, Gamble-George J, Yano H, Khoshbouei H (2017) HIV, tat and dopamine transmission. Neurobiol Dis 105:51–73CrossRefPubMedPubMedCentralGoogle Scholar
  55. Gate D, Rezai-Zadeh K, Jodry D, Rentsendorj A, Town T (2010) Macrophages in Alzheimer's disease: the blood-borne identity. J Neural Transm (Vienna) 117:961–970CrossRefGoogle Scholar
  56. Gelman BB (2015) Neuropathology of HAND with suppressive antiretroviral therapy: encephalitis and neurodegeneration reconsidered. Curr HIV/AIDS Rep 12:272–279CrossRefPubMedPubMedCentralGoogle Scholar
  57. Gelman BB, Spencer JA, Holzer CE 3rd, Soukup VM (2006) Abnormal striatal dopaminergic synapses in national NeuroAIDS tissue consortium subjects with HIV encephalitis. J Neuroimmune Pharmacol 1:410–420CrossRefPubMedGoogle Scholar
  58. Gelman BB, Lisinicchia JG, Chen T, Johnson KM, Jennings K, Freeman DH Jr, Soukup VM (2012) Prefrontal dopaminergic and enkephalinergic synaptic accommodation in HIV-associated neurocognitive disorders and encephalitis. J Neuroimmune Pharmacol 7:686–700CrossRefPubMedPubMedCentralGoogle Scholar
  59. Gill AJ, Kolson DL (2014) Chronic inflammation and the role for cofactors (hepatitis C, drug abuse, antiretroviral drug toxicity, aging) in HAND persistence. Curr HIV/AIDS Rep 11:325–335CrossRefPubMedPubMedCentralGoogle Scholar
  60. Ginhoux F, Lim S, Hoeffel G, Low D, Huber T (2013) Origin and differentiation of microglia. Front Cell Neurosci 7:45CrossRefPubMedPubMedCentralGoogle Scholar
  61. Gjedde A, Kumakura Y, Cumming P, Linnet J, Moller A (2010) Inverted-U-shaped correlation between dopamine receptor availability in striatum and sensation seeking. Proc Natl Acad Sci U S A 107:3870–3875CrossRefPubMedPubMedCentralGoogle Scholar
  62. Glass JD, Fedor H, Wesselingh SL, McArthur JC (1995) Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol 38:755–762CrossRefPubMedGoogle Scholar
  63. Gordon MA, Gordon SB, Musaya L, Zijlstra EE, Molyneux ME, Read RC (2007) Primary macrophages from HIV-infected adults show dysregulated cytokine responses to Salmonella, but normal internalization and killing. AIDS 21:2399–2408CrossRefPubMedGoogle Scholar
  64. Greter M, Lelios I, Croxford AL (2015) Microglia versus myeloid cell nomenclature during brain inflammation. Front Immunol 6:249CrossRefPubMedPubMedCentralGoogle Scholar
  65. Hasko G, Szabo C, Nemeth ZH, Deitch EA (2002) Dopamine suppresses IL-12 p40 production by lipopolysaccharide-stimulated macrophages via a beta-adrenoceptor-mediated mechanism. J Neuroimmunol 122:34–39CrossRefPubMedGoogle Scholar
  66. Hestad K, McArthur JH, Dal Pan GJ, Selnes OA, Nance-Sproson TE, Aylward E, Mathews VP, McArthur JC (1993) Regional brain atrophy in HIV-1 infection: association with specific neuropsychological test performance. Acta Neurol Scand 88:112–118CrossRefPubMedGoogle Scholar
  67. Hollander H, Golden J, Mendelson T, Cortland D (1985) Extrapyramidal symptoms in AIDS patients given low-dose metoclopramide or chlorpromazine. Lancet 2:1186CrossRefPubMedGoogle Scholar
  68. Hong S, Banks WA (2015) Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications. Brain Behav Immun 45:1–12CrossRefPubMedPubMedCentralGoogle Scholar
  69. Horn A, Scheller C, du Plessis S, Arendt G, Nolting T, Joska J, Sopper S, Maschke M, Obermann M, Husstedt IW, Hain J, Maponga T, Riederer P, Koutsilieri E, German Competence Network HA (2013) Increases in CSF dopamine in HIV patients are due to the dopamine transporter 10/10-repeat allele which is more frequent in HIV-infected individuals. J Neural Transm (Vienna) 120:1411–1419CrossRefGoogle Scholar
  70. Hriso E, Kuhn T, Masdeu JC, Grundman M (1991) Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy. Am J Psychiatry 148:1558–1561CrossRefPubMedGoogle Scholar
  71. Hu X, Zhang D, Pang H, Caudle WM, Li Y, Gao H, Liu Y, Qian L, Wilson B, Di Monte DA, Ali SF, Zhang J, Block ML, Hong JS (2008) Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. J Immunol 181:7194–7204CrossRefPubMedPubMedCentralGoogle Scholar
  72. Huang Y, Qiu AW, Peng YP, Liu Y, Huang HW, Qiu YH (2010) Roles of dopamine receptor subtypes in mediating modulation of T lymphocyte function. Neuro Endocrinol Lett 31:782–791PubMedGoogle Scholar
  73. Huck JH, Freyer D, Bottcher C, Mladinov M, Muselmann-Genschow C, Thielke M, Gladow N, Bloomquist D, Mergenthaler P, Priller J (2015) De novo expression of dopamine D2 receptors on microglia after stroke. J Cereb Blood Flow Metab 35:1804–1811CrossRefPubMedPubMedCentralGoogle Scholar
  74. Huffman JC, Fricchione GL (2005) Catatonia and psychosis in a patient with AIDS: treatment with lorazepam and aripiprazole. J Clin Psychopharmacol 25:508–510CrossRefPubMedGoogle Scholar
  75. Iosif RE, Ekdahl CT, Ahlenius H, Pronk CJ, Bonde S, Kokaia Z, Jacobsen SE, Lindvall O (2006) Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis. J Neurosci 26:9703–9712CrossRefPubMedGoogle Scholar
  76. Itoh K, Mehraein P, Weis S (2000) Neuronal damage of the substantia nigra in HIV-1 infected brains. Acta Neuropathol 99:376–384CrossRefPubMedGoogle Scholar
  77. Kalra S, Kalra B, Agrawal N, Kumar S (2011) Dopamine: the forgotten felon in type 2 diabetes. Recent Pat Endocr Metab Immune Drug Discov 5:61–65CrossRefPubMedGoogle Scholar
  78. Kankaanpaa A, Meririnne E, Ariniemi K, Seppala T (2001) Oxalic acid stabilizes dopamine, serotonin, and their metabolites in automated liquid chromatography with electrochemical detection. J Chromatogr B Biomed Sci Appl 753:413–419CrossRefPubMedGoogle Scholar
  79. Kaseda S, Nomoto M, Iwata S (1999) Effect of selegiline on dopamine concentration in the striatum of a primate. Brain Res 815:44–50CrossRefPubMedGoogle Scholar
  80. Katsumoto A, Lu H, Miranda AS, Ransohoff RM (2014) Ontogeny and functions of central nervous system macrophages. J Immunol 193:2615–2621CrossRefPubMedPubMedCentralGoogle Scholar
  81. Kaul M, Lipton SA (2006) Mechanisms of neuronal injury and death in HIV-1 associated dementia. Curr HIV Res 4:307–318CrossRefPubMedGoogle Scholar
  82. Kaul M, Garden GA, Lipton SA (2001) Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 410:988–994CrossRefPubMedGoogle Scholar
  83. Kieburtz KD, Epstein LG, Gelbard HA, Greenamyre JT (1991) Excitotoxicity and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex. Therapeutic implications. Arch Neurol 48:1281–1284CrossRefPubMedGoogle Scholar
  84. Kimmel HL, Ginsburg BC, Howell LL (2005) Changes in extracellular dopamine during cocaine self-administration in squirrel monkeys. Synapse 56:129–134CrossRefPubMedGoogle Scholar
  85. Kleinridders A, Cai W, Cappellucci L, Ghazarian A, Collins WR, Vienberg SG, Pothos EN, Kahn CR (2015) Insulin resistance in brain alters dopamine turnover and causes behavioral disorders. Proc Natl Acad Sci U S A 112:3463–3468CrossRefPubMedPubMedCentralGoogle Scholar
  86. Koob GF (1992) Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 13:177–184CrossRefPubMedGoogle Scholar
  87. Koutsilieri E, Gotz ME, Sopper S, Stahl-Hennig C, Czub M, ter Meulen V, Riederer P (1997) Monoamine metabolite levels in CSF of SIV-infected rhesus monkeys (Macaca mulatta). Neuroreport 8:3833–3836CrossRefPubMedGoogle Scholar
  88. Kraft-Terry SD, Buch SJ, Fox HS, Gendelman HE (2009) A coat of many colors: neuroimmune crosstalk in human immunodeficiency virus infection. Neuron 64:133–145CrossRefPubMedPubMedCentralGoogle Scholar
  89. Kroener S, Chandler LJ, Phillips PE, Seamans JK (2009) Dopamine modulates persistent synaptic activity and enhances the signal-to-noise ratio in the prefrontal cortex. PLoS One 4:e6507CrossRefPubMedPubMedCentralGoogle Scholar
  90. Kumar AM, Fernandez JB, Singer EJ, Commins D, Waldrop-Valverde D, Ownby RL, Kumar M (2009) Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains. J Neuro-Oncol 15:257–274Google Scholar
  91. Kumar AM, Ownby RL, Waldrop-Valverde D, Fernandez B, Kumar M (2011) Human immunodeficiency virus infection in the CNS and decreased dopamine availability: relationship with neuropsychological performance. J Neuro-Oncol 17:26–40Google Scholar
  92. Kure K, Lyman WD, Weidenheim KM, Dickson DW (1990) Cellular localization of an HIV-1 antigen in subacute AIDS encephalitis using an improved double-labeling immunohistochemical method. Am J Pathol 136:1085–1092PubMedPubMedCentralGoogle Scholar
  93. Laengle UW, Markstein R, Pralet D, Seewald W, Roman D (2006) Effect of GLC756, a novel mixed dopamine D1 receptor antagonist and dopamine D2 receptor agonist, on TNF-alpha release in vitro from activated rat mast cells. Exp Eye Res 83:1335–1339CrossRefPubMedGoogle Scholar
  94. Larsson M, Hagberg L, Forsman A, Norkrans G (1991) Cerebrospinal fluid catecholamine metabolites in HIV-infected patients. J Neurosci Res 28:406–409CrossRefPubMedGoogle Scholar
  95. Lassmann H, Schmied M, Vass K, Hickey WF (1993) Bone marrow derived elements and resident microglia in brain inflammation. Glia 7:19–24CrossRefPubMedGoogle Scholar
  96. Leggio GM, Salomone S, Bucolo C, Platania C, Micale V, Caraci F, Drago F (2013) Dopamine D(3) receptor as a new pharmacological target for the treatment of depression. Eur J Pharmacol 719:25–33CrossRefPubMedGoogle Scholar
  97. Levite M (2016) Dopamine and T cells: dopamine receptors and potent effects on T cells, dopamine production in T cells, and abnormalities in the dopaminergic system in T cells in autoimmune, neurological and psychiatric diseases. Acta Physiol (Oxford) 216:42–89CrossRefGoogle Scholar
  98. Li CY, Tsai CS, Chueh SH, Hsu PC, Wang JY, Wong CS, Ho ST (2003) Dobutamine inhibits monocyte chemoattractant protein-1 production and chemotaxis in human monocytes. Anesth Analg 97:205–209 table of contentsCrossRefPubMedGoogle Scholar
  99. Liu Z, Shi Z, Liu J, Wang Y (2014) HIV transactivator of transcription enhances methamphetamine-induced Parkinson's-like behavior in the rats. Neuroreport 25:860–864CrossRefPubMedPubMedCentralGoogle Scholar
  100. Lopez OL, Smith G, Meltzer CC, Becker JT (1999) Dopamine systems in human immunodeficiency virus-associated dementia. Neuropsychiatry Neuropsychol Behav Neurol 12:184–192PubMedGoogle Scholar
  101. Mastroeni D, Grover A, Leonard B, Joyce JN, Coleman PD, Kozik B, Bellinger DL, Rogers J (2009) Microglial responses to dopamine in a cell culture model of Parkinson's disease. Neurobiol Aging 30:1805–1817CrossRefPubMedGoogle Scholar
  102. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, Wodak A, Panda S, Tyndall M, Toufik A, Mattick RP, Reference Group to the UNoHIV, Injecting Drug U (2008) Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 372:1733–1745CrossRefPubMedPubMedCentralGoogle Scholar
  103. McArthur JC (2004) HIV dementia: an evolving disease. J Neuroimmunol 157:3–10CrossRefPubMedGoogle Scholar
  104. Midde NM, Gomez AM, Zhu J (2012) HIV-1 Tat protein decreases dopamine transporter cell surface expression and vesicular monoamine transporter-2 function in rat striatal synaptosomes. J Neuroimmune Pharmacol 7:629–639CrossRefPubMedPubMedCentralGoogle Scholar
  105. Miller AH, Maletic V, Raison CL (2009) Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 65:732–741CrossRefPubMedPubMedCentralGoogle Scholar
  106. Molina JM, Schindler R, Ferriani R, Sakaguchi M, Vannier E, Dinarello CA, Groopman JE (1990) Production of cytokines by peripheral blood monocytes/macrophages infected with human immunodeficiency virus type 1 (HIV-1). J Infect Dis 161:888–893CrossRefPubMedGoogle Scholar
  107. Monje ML, Toda H, Palmer TD (2003) Inflammatory blockade restores adult hippocampal neurogenesis. Science 302:1760–1765CrossRefPubMedGoogle Scholar
  108. Muller N, Schwarz MJ (2010) Immune System and Schizophrenia. Curr Immunol Rev 6:213–220CrossRefPubMedPubMedCentralGoogle Scholar
  109. Nakagome K, Imamura M, Okada H, Kawahata K, Inoue T, Hashimoto K, Harada H, Higashi T, Takagi R, Nakano K, Hagiwara K, Kanazawa M, Dohi M, Nagata M, Matsushita S (2011) Dopamine D1-like receptor antagonist attenuates Th17-mediated immune response and ovalbumin antigen-induced neutrophilic airway inflammation. J Immunol 186:5975–5982CrossRefPubMedGoogle Scholar
  110. Nakano K, Matsushita S, Saito K, Yamaoka K, Tanaka Y (2009a) Dopamine as an immune-modulator between dendritic cells and T cells and the role of dopamine in the pathogenesis of rheumatoid arthritis. Nihon Rinsho Meneki Gakkai Kaishi 32:1–6CrossRefPubMedGoogle Scholar
  111. Nakano K, Higashi T, Takagi R, Hashimoto K, Tanaka Y, Matsushita S (2009b) Dopamine released by dendritic cells polarizes Th2 differentiation. Int Immunol 21:645–654CrossRefPubMedGoogle Scholar
  112. Nakano K, Yamaoka K, Hanami K, Saito K, Sasaguri Y, Yanagihara N, Tanaka S, Katsuki I, Matsushita S, Tanaka Y (2011) Dopamine induces IL-6-dependent IL-17 production via D1-like receptor on CD4 naive T cells and D1-like receptor antagonist SCH-23390 inhibits cartilage destruction in a human rheumatoid arthritis/SCID mouse chimera model. J Immunol 186:3745–3752CrossRefPubMedGoogle Scholar
  113. Navia BA, Cho ES, Petito CK, Price RW (1986) The AIDS dementia complex: II. Neuropathology. Ann Neurol 19:525–535CrossRefPubMedGoogle Scholar
  114. Nolan R, Gaskill PJ (2018) The role of Catecholamines in HIV Neuropathogenesis. Brain Res.  https://doi.org/10.1016/j.brainres.2018.04.030 CrossRefPubMedGoogle Scholar
  115. Obermann M, Kuper M, Kastrup O, Yaldizli O, Esser S, Thiermann J, Koutsilieri E, Arendt G, Diener HC, Maschke M, German Competence Network HA (2009) Substantia nigra hyperechogenicity and CSF dopamine depletion in HIV. J Neurol 256:948–953CrossRefPubMedGoogle Scholar
  116. Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P, Giustetto M, Ferreira TA, Guiducci E, Dumas L, Ragozzino D, Gross CT (2011) Synaptic pruning by microglia is necessary for normal brain development. Science 333:1456–1458CrossRefPubMedGoogle Scholar
  117. Patterson PH (2009) Immune involvement in schizophrenia and autism: etiology, pathology and animal models. Behav Brain Res 204:313–321CrossRefPubMedGoogle Scholar
  118. Peeters M, Maloteaux JM, Hermans E (2003) Distinct effects of amantadine and memantine on dopaminergic transmission in the rat striatum. Neurosci Lett 343:205–209CrossRefPubMedGoogle Scholar
  119. Pierce RC, Kumaresan V (2006) The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav Rev 30:215–238CrossRefPubMedGoogle Scholar
  120. Pinoli M, Marino F, Cosentino M (2017) Dopaminergic regulation of innate immunity: a review. J Neuroimmune Pharmacol 12:602–623CrossRefPubMedGoogle Scholar
  121. Prado C, Contreras F, Gonzalez H, Diaz P, Elgueta D, Barrientos M, Herrada AA, Lladser A, Bernales S, Pacheco R (2012) Stimulation of dopamine receptor D5 expressed on dendritic cells potentiates Th17-mediated immunity. J Immunol 188:3062–3070CrossRefPubMedGoogle Scholar
  122. Prinz M, Priller J (2014) Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat Rev Neurosci 15:300–312CrossRefPubMedGoogle Scholar
  123. Prinz M, Tay TL, Wolf Y, Jung S (2014) Microglia: unique and common features with other tissue macrophages. Acta Neuropathol 128:319–331CrossRefPubMedGoogle Scholar
  124. Qin T, Wang C, Chen X, Duan C, Zhang X, Zhang J, Chai H, Tang T, Chen H, Yue J, Li Y, Yang J (2015) Dopamine induces growth inhibition and vascular normalization through reprogramming M2-polarized macrophages in rat C6 glioma. Toxicol Appl Pharmacol 286:112–123CrossRefPubMedGoogle Scholar
  125. Ransohoff RM, Cardona AE (2010) The myeloid cells of the central nervous system parenchyma. Nature 468:253–262CrossRefPubMedGoogle Scholar
  126. Rao VR, Ruiz AP, Prasad VR (2014) Viral and cellular factors underlying neuropathogenesis in HIV associated neurocognitive disorders (HAND). AIDS Res Ther 11:13CrossRefPubMedPubMedCentralGoogle Scholar
  127. Rappaport J, Volsky DJ (2015) Role of the macrophage in HIV-associated neurocognitive disorders and other comorbidities in patients on effective antiretroviral treatment. J Neuro-Oncol 21:235–241Google Scholar
  128. Reyes MG, Faraldi F, Senseng CS, Flowers C, Fariello R (1991) Nigral degeneration in acquired immune deficiency syndrome (AIDS). Acta Neuropathol 82:39–44CrossRefPubMedGoogle Scholar
  129. Ricci A, Mariotta S, Greco S, Bisetti A (1997) Expression of dopamine receptors in immune organs and circulating immune cells. Clin Exp Hypertens 19:59–71CrossRefPubMedGoogle Scholar
  130. Rogers J, Mastroeni D, Leonard B, Joyce J, Grover A (2007) Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder? Int Rev Neurobiol 82:235–246CrossRefPubMedGoogle Scholar
  131. Rohr O, Sawaya BE, Lecestre D, Aunis D, Schaeffer E (1999) Dopamine stimulates expression of the human immunodeficiency virus type 1 via NF-kappaB in cells of the immune system. Nucleic Acids Res 27:3291–3299CrossRefPubMedPubMedCentralGoogle Scholar
  132. Rouzine IM, Weinberger AD, Weinberger LS (2015) An evolutionary role for HIV latency in enhancing viral transmission. Cell 160:1002–1012CrossRefPubMedPubMedCentralGoogle Scholar
  133. Ruelas DS, Greene WC (2013) An integrated overview of HIV-1 latency. Cell 155:519–529CrossRefPubMedPubMedCentralGoogle Scholar
  134. Sampson TR, Mazmanian SK (2015) Control of brain development, function, and behavior by the microbiome. Cell Host Microbe 17:565–576CrossRefPubMedPubMedCentralGoogle Scholar
  135. Sanford R, Fellows LK, Ances BM, Collins DL (2018) Association of brain structure changes and cognitive function with combination antiretroviral therapy in HIV-positive individuals. JAMA Neurol 75:72–79.CrossRefPubMedGoogle Scholar
  136. Sanford R, Fernandez Cruz AL, Scott SC, Mayo NE, Fellows LK, Ances BM, Collins DL (2017b) Regionally specific brain volumetric and cortical thickness changes in HIV-infected patients in the HAART era. J Acquir Immune Defic Syndr 74:563–570CrossRefPubMedPubMedCentralGoogle Scholar
  137. Sarkar C, Chakroborty D, Chowdhury UR, Dasgupta PS, Basu S (2008) Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models. Clin Cancer Res 14:2502–2510CrossRefPubMedGoogle Scholar
  138. Sarkar C, Basu B, Chakroborty D, Dasgupta PS, Basu S (2010) The immunoregulatory role of dopamine: an update. Brain Behav Immun 24:525–528CrossRefPubMedGoogle Scholar
  139. Saylor D, Dickens AM, Sacktor N, Haughey N, Slusher B, Pletnikov M, Mankowski JL, Brown A, Volsky DJ, McArthur JC (2016) HIV-associated neurocognitive disorder--pathogenesis and prospects for treatment. Nat Rev Neurol 12:234–248CrossRefPubMedPubMedCentralGoogle Scholar
  140. Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R, Ransohoff RM, Greenberg ME, Barres BA, Stevens B (2012) Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 74:691–705CrossRefPubMedPubMedCentralGoogle Scholar
  141. Schafer DP, Lehrman EK, Stevens B (2013) The "quad-partite" synapse: microglia-synapse interactions in the developing and mature CNS. Glia 61:24–36CrossRefPubMedGoogle Scholar
  142. Scheller C, Arendt G, Nolting T, Antke C, Sopper S, Maschke M, Obermann M, Angerer A, Husstedt IW, Meisner F, Neuen-Jacob E, Muller HW, Carey P, Ter Meulen V, Riederer P, Koutsilieri E (2010) Increased dopaminergic neurotransmission in therapy-naive asymptomatic HIV patients is not associated with adaptive changes at the dopaminergic synapses. J Neural Transm (Vienna) 117:699–705CrossRefGoogle Scholar
  143. Schiffer WK, Marsteller D, Dewey SL (2003) Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine. Psychopharmacology 168:339–343CrossRefPubMedGoogle Scholar
  144. Schouten J, Cinque P, Gisslen M, Reiss P, Portegies P (2011) HIV-1 infection and cognitive impairment in the cART era: a review. AIDS 25:561–575CrossRefPubMedGoogle Scholar
  145. Senogles SE (2007) D2 dopamine receptor-mediated antiproliferation in a small cell lung cancer cell line, NCI-H69. Anti-Cancer Drugs 18:801–807CrossRefPubMedGoogle Scholar
  146. Sevigny JJ, Albert SM, McDermott MP, McArthur JC, Sacktor N, Conant K, Schifitto G, Selnes OA, Stern Y, McClernon DR, Palumbo D, Kieburtz K, Riggs G, Cohen B, Epstein LG, Marder K (2004) Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 63:2084–2090CrossRefPubMedPubMedCentralGoogle Scholar
  147. Shavali S, Combs CK, Ebadi M (2006) Reactive macrophages increase oxidative stress and alpha-synuclein nitration during death of dopaminergic neuronal cells in co-culture: relevance to Parkinson's disease. Neurochem Res 31:85–94CrossRefPubMedGoogle Scholar
  148. Shen Y, Ye MY (1993) Determination of the stability of dopamine in aqueous solutions by high performance liquid chromatography. J Liq Chromatogr 17:1557–1565CrossRefGoogle Scholar
  149. Sloviter RS, Connor JD (1977) Postmortem stability of norepinephrine, dopamine, and serotonin in rat brain. J Neurochem 28:1129–1131CrossRefPubMedGoogle Scholar
  150. Smits HA, Boven LA, Pereira CF, Verhoef J, Nottet HS (2000) Role of macrophage activation in the pathogenesis of Alzheimer's disease and human immunodeficiency virus type 1-associated dementia. Eur J Clin Investig 30:526–535CrossRefGoogle Scholar
  151. Soontornniyomkij V (2017) Neuropathology of HIV-1 disease. In: Shapshak P, Levine AJ, Foley BT, Somboonwit C, Singer E, Chiappelli F, Sinnott JT (eds) Global virology II - HIV and NeuroAIDS. Springer New York, New York, pp 143–208CrossRefGoogle Scholar
  152. Spanagel R, Eilbacher B, Wilke R (1994) Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat--a pharmacokinetic microdialysis study. Eur J Pharmacol 262:21–26CrossRefPubMedGoogle Scholar
  153. Strathdee SA, Stockman JK (2010) Epidemiology of HIV among injecting and non-injecting drug users: current trends and implications for interventions. Current HIV/AIDS Reports 7:99–106CrossRefPubMedPubMedCentralGoogle Scholar
  154. Strell C, Sievers A, Bastian P, Lang K, Niggemann B, Zanker KS, Entschladen F (2009) Divergent effects of norepinephrine, dopamine and substance P on the activation, differentiation and effector functions of human cytotoxic T lymphocytes. BMC Immunol 10:62CrossRefPubMedPubMedCentralGoogle Scholar
  155. Stuerenburg HJ, Petersen K, Baumer T, Rosenkranz M, Buhmann C, Thomasius R (2002) Plasma concentrations of 5-HT, 5-HIAA, norepinephrine, epinephrine and dopamine in ecstasy users. Neuro Endocrinol Lett 23:259–261PubMedGoogle Scholar
  156. Sun C, Sun L, Ma H, Peng J, Zhen Y, Duan K, Liu G, Ding W, Zhao Y (2012) The phenotype and functional alterations of macrophages in mice with hyperglycemia for long term. J Cell Physiol 227:1670–1679CrossRefPubMedGoogle Scholar
  157. Syslova K, Rambousek L, Kuzma M, Najmanova V, Bubenikova-Valesova V, Slamberova R, Kacer P (2011) Monitoring of dopamine and its metabolites in brain microdialysates: method combining freeze-drying with liquid chromatography-tandem mass spectrometry. J Chromatogr A 1218:3382–3391CrossRefPubMedGoogle Scholar
  158. Tanda G, Carboni E, Frau R, Di Chiara G (1994) Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology 115:285–288CrossRefPubMedGoogle Scholar
  159. Tavazzi E, Morrison D, Sullivan P, Morgello S, Fischer T (2014) Brain inflammation is a common feature of HIV-infected patients without HIV encephalitis or productive brain infection. Curr HIV Res 12:97–110CrossRefPubMedPubMedCentralGoogle Scholar
  160. Torres KC, Antonelli LR, Souza AL, Teixeira MM, Dutra WO, Gollob KJ (2005) Norepinephrine, dopamine and dexamethasone modulate discrete leukocyte subpopulations and cytokine profiles from human PBMC. J Neuroimmunol 166:144–157CrossRefPubMedGoogle Scholar
  161. Trudler D, Weinreb O, Mandel SA, Youdim MB, Frenkel D (2014) DJ-1 deficiency triggers microglia sensitivity to dopamine toward a pro-inflammatory phenotype that is attenuated by rasagiline. J Neurochem 129:434–447CrossRefPubMedGoogle Scholar
  162. UNAIDS G (2016) Global AIDS update 2016. World Health Organization Library, Geneva, SwitzerlandGoogle Scholar
  163. Underwood J, Cole JH, Caan M, De Francesco D, Leech R, van Zoest RA, Su T, Geurtsen GJ, Schmand BA, Portegies P, Prins M, Wit FW, Sabin CA, Majoie C, Reiss P, Winston A, Sharp DJ (2017) Gray and white matter abnormalities in treated HIV-disease and their relationship to cognitive function. Clin Infect Dis 65:422–432Google Scholar
  164. UNODC (2017) World drug report 2017. In: United NationsGoogle Scholar
  165. van den Dries LWJ, Wagener MN, Jiskoot LC, Visser M, Robertson KR, Adriani KS, van Gorp ECM (2017) Neurocognitive impairment in a chronically well-suppressed HIV-infected population: the Dutch TREVI cohort study. AIDS Patient Care STDs 31:329–334CrossRefPubMedGoogle Scholar
  166. Via MA, Chandra H, Araki T, Potenza MV, Skamagas M (2010) Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes. Diabetes Metab Syndr Obes 3:43–48CrossRefPubMedPubMedCentralGoogle Scholar
  167. Volkow ND, Wang G, Fowler JS, Logan J, Gerasimov M, Maynard L, Ding Y, Gatley SJ, Gifford A, Franceschi D (2001) Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 21:RC121CrossRefPubMedGoogle Scholar
  168. Wake H, Moorhouse AJ, Jinno S, Kohsaka S, Nabekura J (2009) Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. J Neurosci 29:3974–3980CrossRefPubMedGoogle Scholar
  169. Wake H, Moorhouse AJ, Miyamoto A, Nabekura J (2013) Microglia: actively surveying and shaping neuronal circuit structure and function. Trends Neurosci 36:209–217CrossRefPubMedGoogle Scholar
  170. Wang PS, Walker AM, Tsuang MT, Orav EJ, Glynn RJ, Levin R, Avorn J (2002) Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 59:1147–1154CrossRefPubMedGoogle Scholar
  171. Wang M, Vijayraghavan S, Goldman-Rakic PS (2004) Selective D2 receptor actions on the functional circuitry of working memory. Science 303:853–856CrossRefPubMedGoogle Scholar
  172. Watanabe Y, Nakayama T, Nagakubo D, Hieshima K, Jin Z, Katou F, Hashimoto K, Yoshie O (2006) Dopamine selectively induces migration and homing of naive CD8+ T cells via dopamine receptor D3. J Immunol 176:848–856CrossRefPubMedGoogle Scholar
  173. Watkins CC, Treisman GJ (2012) Neuropsychiatric complications of aging with HIV. J Neuro-Oncol 18:277–290Google Scholar
  174. Wiley CA, Nelson JA (1990) Human immunodeficiency virus: infection of the nervous system. Curr Top Microbiol Immunol 160:157–172PubMedGoogle Scholar
  175. Williams KC, Hickey WF (2002) Central nervous system damage, monocytes and macrophages, and neurological disorders in AIDS. Annu Rev Neurosci 25:537–562CrossRefPubMedGoogle Scholar
  176. Wood M, Reavill C (2007) Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert Opin Investig Drugs 16:771–775CrossRefPubMedGoogle Scholar
  177. Wu Y, Dissing-Olesen L, MacVicar BA, Stevens B (2015) Microglia: dynamic mediators of synapse development and plasticity. Trends Immunol 36:605–613CrossRefPubMedPubMedCentralGoogle Scholar
  178. Yamamoto S, Ohta N, Matsumoto A, Horiguchi Y, Koide M, Fujino Y (2016) Haloperidol suppresses NF-kappaB to inhibit lipopolysaccharide-induced pro-inflammatory response in RAW 264 cells. Med Sci Monit 22:367–372CrossRefPubMedPubMedCentralGoogle Scholar
  179. Yan Y, Jiang W, Liu L, Wang X, Ding C, Tian Z, Zhou R (2015) Dopamine controls systemic inflammation through inhibition of NLRP3 Inflammasome. Cell 160:62–73CrossRefPubMedGoogle Scholar
  180. Yirmiya R, Goshen I (2011) Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun 25:181–213CrossRefPubMedGoogle Scholar
  181. Yoshioka Y, Sugino Y, Tozawa A, Yamamuro A, Kasai A, Ishimaru Y, Maeda S (2016) Dopamine inhibits lipopolysaccharide-induced nitric oxide production through the formation of dopamine quinone in murine microglia BV-2 cells. J Pharmacol Sci 130:51–59CrossRefPubMedGoogle Scholar
  182. Zachek MK, Takmakov P, Park J, Wightman RM, McCarty GS (2010) Simultaneous monitoring of dopamine concentration at spatially different brain locations in vivo. Biosens Bioelectron 25:1179–1185CrossRefPubMedGoogle Scholar
  183. Zhang L, Zhou FM, Dani JA (2004) Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release. Mol Pharmacol 66:538–544CrossRefPubMedGoogle Scholar
  184. Zhang Y, Cuevas S, Asico LD, Escano C, Yang Y, Pascua AM, Wang X, Jones JE, Grandy D, Eisner G, Jose PA, Armando I (2012) Deficient dopamine D2 receptor function causes renal inflammation independently of high blood pressure. PLoS One 7:e38745CrossRefPubMedPubMedCentralGoogle Scholar
  185. Zhang Y, Chen Y, Wu J, Manaenko A, Yang P, Tang J, Fu W, Zhang JH (2015) Activation of dopamine D2 receptor suppresses Neuroinflammation through alphaB-crystalline by inhibition of NF-kappaB nuclear translocation in experimental ICH mice model. Stroke 46:2637–2646CrossRefPubMedPubMedCentralGoogle Scholar
  186. Zhu J, Mactutus CF, Wallace DR, Booze RM (2009) HIV-1 Tat protein-induced rapid and reversible decrease in [3H]dopamine uptake: dissociation of [3H]dopamine uptake and [3H]2beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane (WIN 35,428) binding in rat striatal synaptosomes. J Pharmacol Exp Ther 329:1071–1083CrossRefPubMedPubMedCentralGoogle Scholar
  187. Zhu J, Yuan Y, Midde NM, Gomez AM, Sun WL, Quizon PM, Zhan CG (2016) HIV-1 transgenic rats display an increase in [(3)H]dopamine uptake in the prefrontal cortex and striatum. J Neuro-Oncol 22:282–292Google Scholar
  188. Zhu J, Hu Z, Han X, Wang D, Jiang Q, Ding J, Xiao M, Wang C, Lu M, Hu G (2018) Dopamine D2 receptor restricts astrocytic NLRP3 inflammasome activation via enhancing the interaction of beta-arrestin2 and NLRP3. Cell Death Differ 25:2037–2049CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pharmacology and PhysiologyDrexel University College of MedicinePhiladelphiaUSA
  2. 2.Division of Infectious Diseases and HIV MedicineDrexel University College of MedicinePhiladelphiaUSA

Personalised recommendations